4 results
Part I (dose-escalation): to evaluate the safety of SYD985 and to determine the Maximum Tolerated Dose and Recommended Phase 2 DosePart II (expanded cohorts): to evaluate the Objective tumour Response Rate
To investigate efficacy of ASP6294 in female subjects with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC).To investigate safety and tolerability of ASP6294 in female subjects with BPS/IC.To investigate the pharmacokinetics and pharmacodynamics…
Primary Part 1: To investigate the effect of multiple oral doses of rifampicin on the pharmacokinetics (PK) of a single oral dose of RO7017773 in healthy participants.Part 2: To investigate the effect of multiple oral doses of gemfibrozil on the PK…
The primary objective of this study is to demonstrate that SYD985 is superior to physician*s choice in prolonging progression-free survival (PFS) on the basis of the blinded independent central review of tumour assessment.The secondary objectives of…